Bionomics Limited/fi Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Lynx1 Capital Management LP and Weston Nichols, holding a 16.3% stake in Neuphoria Therapeutics, have made an all-cash or stock offer to acquire certain intellectual property assets from the company.
Lynx1 Capital Management LP has submitted a recalculated non-binding proposal to acquire Neuphoria Therapeutics Inc. for $4.75 per share in cash, adjusting for recent share dilution.
SCHEDULE 13D/A: Lynx1 Capital to Resubmit Neuphoria Buyout Offer
Lynx1 Capital Management plans to resubmit a revised offer to acquire Neuphoria Therapeutics Inc. after the company ceased its dilutive share issuances.
Lynx1 Capital Management has withdrawn its $5.20 per share acquisition offer for Neuphoria Therapeutics, citing 'reckless' share issuances and significant shareholder dilution.
Lynx1 Capital Management LP has proposed to acquire all outstanding shares of Neuphoria Therapeutics Inc. for $5.20 per share in cash, representing a 27% premium.
Lynx1 Capital Management LP and Weston Nichols have disclosed a 37.1% beneficial ownership stake in Neuphoria Therapeutics Inc., citing undervaluation and potential strategic engagement.
Apeiron Investment Group and its affiliates have sold shares of Neuphoria Therapeutics Inc., reducing their beneficial ownership to 4.5% following the company's redomiciliation.